STABILIZATION OF THE ANTI-CD20 ANTIBODY RITUXIMAB
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 2, 2014
app pub date -
Jan 19, 2012
filing date -
Jan 19, 2012
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The invention provides isolated stabilized anti-CD20 antibodies and methods of their manufacture and use in diagnosis and treatment animal diseases including human lymphoma, leukemia, and autoimmunity.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C12N:MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF
- G01N:INVESTIGATING OR ANALYSING MATERIALS BY DETERMININ....
- A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....
- C40B:COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL ....
- C07K:PEPTIDES
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully